LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunity.
Keshri. Anand K AK; Rawat. Suraj S SS; Chaudhary. Anubha A; Sharma. Swati S; Kapoor. Ananya A; Mehra. Parul P; Kaur. Rimanpreet R; Mishra. Amit A; Prasad. Amit A
Key Findings
- LL-37 disrupts microbial membranes, stopping infections
- It can modulate immune responses and may have anti‑cancer effects
- Research is still early and practical dosing or safety for humans isn’t established
Practical Outcomes
- Right now there’s no proven way to safely take LL‑37 for health benefits. Keep an eye on future studies, but for now focus on proven strategies like good sleep, diet, and exercise.
Summary
LL-37 is a natural protein that can kill bacteria, fungi and viruses and also helps the immune system fight cancer, but most of what we know comes from lab studies and it isn’t yet a ready‑to‑use supplement.
Abstract
Antimicrobial peptides (AMPs) represent a unique group of naturally occurring molecules having diverse biological activities, including potent antimicrobial properties. Among them, LL-37 has emerged as a significant player, demonstrating its multifaceted roles during bacterial, fungal, and viral infections, as well as exhibiting intriguing implications in cancer. This review delves into the versatile functions of LL-37, elucidating its mechanisms of action against microbial pathogens and its potential to modulate immune responses. We explored the efficacy of LL-37 in disrupting bacterial membranes, inhibiting fungal growth, and interfering with viral replication, highlighting its potential as a therapeutic agent against a wide array of infectious diseases. Furthermore, we discussed the emerging role of LL-37 in cancer immunity, where its immunomodulatory effects and direct cytotoxicity towards cancer cells offer novel avenues for cancer therapy in the near future. We provided a comprehensive overview of the activities of LL-37 across various diseases and underscored the importance of further research into harnessing the therapeutic potential of this potential antimicrobial peptide along with other suitable candidates.
Study Information
pubmed
2024
2024-12-04T00:00:00.000Z
10.1016/j.ijantimicag.2024.107398
7
193